Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 09 2020 - 8:30AM
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage
biopharmaceutical company focused on the development of innovative
therapies to treat central nervous system (CNS) disorders, today
announced that it will participate in the virtual H.C. Wainwright
22nd Annual Global Investment Conference on September 16, 2020 at
10:00 a.m. Eastern Time.
The presentation will be webcast and accessible on a live and
archived basis through the investor relations section of the
Company’s web site,
http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva’s portfolio of compounds includes: roluperidone
(MIN-101), in clinical development for schizophrenia; a potential
royalty stream from seltorexant (MIN-202 or JNJ-42847922), in
clinical development for insomnia and MDD; and MIN-301, in
pre-clinical development for Parkinson’s disease. Minerva’s common
stock is listed on the NASDAQ Global Market under the symbol
“NERV.” For more information, please visit
www.minervaneurosciences.com.
Contact:
William B. BoniVP, Investor Relations/Corp.
CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024